Xilio Therapeutics shares are trading higher after the company announced it will present its initial Phase 1c dose escalation data for XTX101 in combination with Atezolizumab at the SITC 39th annual meeting.
Portfolio Pulse from Benzinga Newsdesk
Xilio Therapeutics shares rise as the company announces it will present initial Phase 1c dose escalation data for XTX101 in combination with Atezolizumab at the SITC 39th annual meeting.
October 30, 2024 | 3:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Xilio Therapeutics shares are trading higher following the announcement of presenting initial Phase 1c data for XTX101 with Atezolizumab at a major conference.
The announcement of presenting initial Phase 1c data at a significant conference suggests positive developments in Xilio's drug pipeline, likely boosting investor confidence and driving the stock price up.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90